Search Blog
November 2013
« Oct   Dec »


Oxygen Biotherapeutics (OXBT) Rise Sheds Light On OxySure Systems (OXYS)


By TDM Financial Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) has risen more than 175% over the past week or so on massive trading volumes, after announcing a broadening of their product lines through a licensing agreement.

Broadening Product Lines 

Oxygen Biotherapeutics’ recent move represents an addition to its original business developing medical products that promises to deliver oxygen to tissues in the body. The company’s flagship Oxycyte® technology is a systemic perfluorocarbon (“PFC”) that delivers oxygen to vital organs in the case of acute ischemia. Similar products are also in development for use in personal care, topical wound healing and other topical indications. 

While Oxygen Biotherapeutics has been successful in two clinical trials and is currently being evaluated in a Phase IIB clinical trial for traumatic brain injury (“TBI”), management plans to focus the majority of its efforts on its two advanced topical products, Dermacyte® and Wundecyte®, given their significantly near-term potential. The firm is also developing Vitavent™, which is an oxygen exchange fluid for the treatment of lung conditions, and other products.

Benefiting from the Exposure OxySure Systems, Inc. (OTCBB: OXYS), a medical technology company focused on the design, manufacture and distribution of specialty medical and respiratory solutions, could benefit from the oxygen industry’s enhance exposure. The company pioneered an FDA-approved solution to produce medical pure oxygen from dry, inert powders for emergency and short-duration use, while the device itself can be used by any layperson in the event of a medical emergency.

With the potential to become the equivalent of the next AED in the medium term and the equivalent of a fire extinguisher in the long term, OxySure’s Model 615, already FDA approved for over the counter sale (no prescription required), has a significantly larger end market than Oxygen Biotherapeutics PFC-based drugs. The installed base for AEDs exceeds two million units, while fire extinguishers exceed 100 million units in the U.S. alone. Capturing just a fraction of this market with its unique emergency oxygen solution could represent a multi-billion dollar opportunity that could unlock significant long-term shareholder value. It is more likely than not that OxySure will capture a significant share of the market because it is the only player that has this product and technology. OxySure pioneered this technology, and owns numerous patents and patents pending around it, and has first mover advantage. 

Potential Investment Opportunity 

OxySure Systems represents a compelling investment opportunity, with a market capitalization of just $18 million. During the second quarter, the company reported revenues that soared more than 650% to $476,071, SG&A expenses that fell 18% to $194,803, interest expenses that fell 60% to $23,254, and a net loss that fell 11.8%. Recently, Sterling Investments analysts issued a buy rating on the stock with a $1.90 per share 12-month price target. 

The positive financial momentum has been followed by a number of promising recent developments. In July, the company launched an AED/OxySure double wall cabinet to house its product next to the ubiquitous AED. In October, the firm announced a partnership that lets dozens of banks compete for leases on OxySure’s products with a simple 2-minute application. Creating the ability for customers to lease OxySure’s products significantly expands the market. Combined, these two developments could significant expand its market moving forward.

More Information:

About Emerging Growth LLC:

EGC is a marketing and consulting firm that specializes in creating ongoing communications strategies for public and private companies.


Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. For full disclosure please visit: